The contact activation inhibitor and factor XI antibody, AB023, produces safe, dose-dependent anticoagulation in a phase 1 first-in-human trial

OBJECTIVE: Factor XI (FXI) contributes to thrombotic disease while playing a limited role in normal hemostasis. We generated a unique, humanized anti-FXI antibody, AB023, which blocks factor XIIa (FXIIa)-mediated FXI activation without inhibiting FXI activation by thrombin or the procoagulant functi...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Arterioscler Thromb Vasc Biol
Main Authors: Lorentz, Christina U., Verbout, Norah G., Wallisch, Michael, Hagen, Matthew W., Shatzel, Joseph J., Olson, Sven R., Puy, Cristina, Hinds, Monica T., McCarty, Owen J.T., Gailani, David, Gruber, András, Tucker, Erik. I.
Format: Artigo
Sprog:Inglês
Udgivet: 2019
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6494446/
https://ncbi.nlm.nih.gov/pubmed/30700130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/ATVBAHA.118.312328
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker